Exclusion of patients with brain metastases from cancer clinical trials

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Albany Medical College, Albany, New York.
³ The University of Texas Health Science Center McGovern Medical School, Houston, Texas.
⁴ The Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁵ The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee.
⁶ Baylor College of Medicine, Houston, Texas.
⁷ New York University Langone School of Medicine, New York, New York.

Roshal R Patel et al. Neuro Oncol. 2020.

. 2020 Apr 15;22(4):577-579.

doi: 10.1093/neuonc/noz246.

¹ The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Albany Medical College, Albany, New York.
³ The University of Texas Health Science Center McGovern Medical School, Houston, Texas.
⁴ The Johns Hopkins University School of Medicine, Baltimore, Maryland.
⁵ The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee.
⁶ Baylor College of Medicine, Houston, Texas.
⁷ New York University Langone School of Medicine, New York, New York.

No abstract available

References

1. Cagney DN, Martin AM, Catalano PJ, et al. . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–1521. - PMC - PubMed
1. Harvey RD, Rubinstein WS, Ison G, et al. . Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: real-world analysis. J Clin Oncol. 2019;37(18_suppl): LBA108–LBA108. - PubMed
1. Lin NU, Prowell T, Tan AR, et al. . Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research brain metastases working group. J Clin Oncol. 2017;35(33):3760–3773. - PubMed
1. Camidge DR, Lee EQ, Lin NU, et al. . Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology brain metastases working group. Lancet Oncol. 2018;19(1):e20–e32. - PubMed
1. US Department of Health and Human Services, Food and Drug Administration. Cancer Clinical Trial Eligibility Criteria: Brain Metastases Guidance for Industry March 2019. https://www.fda.gov/media/121317/download. Accessed December 3, 2019.